If you are looking for some new portfolio additions, then it could be worth considering the three ASX shares listed below.
That's because they have just been named as buys by analysts at Morgans. Here's what they are recommending to clients:
Image source: Getty Images
Credit Corp Ltd (ASX: CCP)
The team at Morgans believes that this debt collector's shares are still undervalued despite rocketing higher since the release of a strong full year result.
The broker has put a buy rating and $21.50 price target on its shares. It commented:
CCP's FY25 NPAT of A$94.1m, +16% on pcp, was inline. The upper-end of FY26 NPAT guidance of A$100-110m (mid-point +12%) was above consensus expectations. CCP's guidance reflects management's incremental confidence in the US operations and growth path. CCP's FY26/27 growth outlook is reliant on strong growth being delivered from the US.
The investment pipeline is more secure and diverse; and operational efficiency has improved. Group guidance implies >40% US segment growth in FY26. Execution in the US looks to be on track, with incremental investment in Lending and stabilised domestic earnings. Continuing to deliver earnings momentum in the US is the key catalyst. We view the valuation as undemanding.
ResMed Inc. (ASX: RMD)
Morgans was impressed with another strong result from ResMed last week. It notes that the sleep disorder treatment company delivered a result ahead of expectations.
In light of this, the broker has reaffirmed its accumulate rating with an improved price target of $47.86. It said:
4Q results were above expectations, with high-single digit revenue growth, expanding operating leverage, and strong operating cash flow. Sleep and respiratory sales were solid, with resupply and new patient set-ups supporting Americas mask growth, while ROW tracked the market and residential care software sales surprised to the upside posting high-single digit gains.
GPM continues to expand, underpinned by procurement gains, manufacturing efficiencies and favourable FX, while OPM grew on good cost control. Notably, FY26 GPM is pegged at 61-63% (200bp at mid-point yoy), highlighting management's confidence in a solid outlook, with strong cash flow supporting growing dividends and share buy backs, we continue to view the fundamentals as sound and the company in a strong position.
SKS Technologies Group Ltd (ASX: SKS)
Another ASX share that Morgans is positive on is SKS Technologies. It specialises in the design and installation of electrical, audio visual, and communication networking solutions.
Morgans notes that SKS technologies has pre-released its results and revealed strong growth in FY 2025. In light of this, the broker has reaffirmed its buy rating with an improved price target of $2.75. It said:
SKS recently pre-reported FY25 revenue of $259.5m (+90% vs FY24), in line with guidance. The group also delivered better than expected operating leverage for FY25, delivering PBT of $20.8m, +15% ahead of MorgF $18.2m (PBT margin 8%). We see SKS' margins as sustainable as the group continues to scale and rebase our forecasts for this new PBT margin baseline, driving ~15% PBT upgrades in FY25-27F. We retain our BUY rating with a revised PT of $2.75/sh (from $2.30/sh).
